Loading
A phase 1/2 trial of Calderasib, Patritumab deruxtecan, Sacituzumab tirumotecan and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) is a phase 1/2 interventional study registered as NCT07286149 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2026-04-30 and due to reach its primary completion in 2029-08-17. Interventions recorded: MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab and Rescue Medications.
Shares Calderasib, Sacituzumab tirumotecan, Cetuximab, Merck & Co. (MSD) and the tag pipeline.
Shares Calderasib, Cetuximab, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.